OSL AgentPay enables developer AI agents to make autonomous intent-based payments via stablecoins, empowering the rapidly growing AI-driven economic activity worldwide. HONG KONG, Aug. 07, 2026 (GLOBE NEWSWIRE) — OSL Group (HKEX: 863) (“OSL”), a global stablecoin payment and trading platform, today announced the launch of OSL AgentPay, a stablecoin payment infrastructure designed for AI agents. AgentPay enables developer AI agents to execute autonomous intent-based payment flows, meeting the high-frequency, micro-value payment demands between agents. AgentPay will support multiple stablecoins (including USDT, USDC, USDGO, and more) and multiple payment protocols (x402, AP2, MPP, and more). Developers can now integrate via API from today. Over the longer term, OSL intends to leverage this momentum to drive adoption of...

HONG KONG, Aug. 07, 2026 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that it will report its financial results for the second quarter ended June 30, 2026, before U.S. markets open on August 20, 2026. Futu’s management will hold an earnings conference call on Thursday, August 20, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Please note that all participants will need to pre-register for the conference call, using the link https://register-conf.media-server.com/register/BIc3f2e0e4bf004756b6d281e81ca215dd It will automatically lead to the registration page of “Futu Holdings Ltd Second Quarter 2026 Earnings Conference Call”, where details for RSVP are...

€ 750,000,000 5.375 per cent. Sustainability Linked Bonds due 28 May 2027 under the €5,000,000,000 Euro Medium Term Note Programme (The “Programme”)Series N°13Tranche N°1ISIN Code: FR001400EA167 August 2026, Paris – Reference is made to the terms and conditions (the “Terms and Conditions”) included in the base prospectus dated 14 June 2022 approved by the Autorité des marchés financiers under no. 22-211 on 14 June 2022 (as supplemented by a supplement approved by the Autorité des marchés financiers under no. 22-456 on 21 November 2022) (the “Base Prospectus”), as completed by the final terms dated 25 November 2022 (the “Final Terms”), of the EUR 750,000,000 aggregate principal amount of 5.375 per cent. Notes due 28 May 2027 (the “Notes”) issued by Valeo SE (the “Issuer”).  All capitalized terms used herein and not otherwise defined...

Tokyo, Japan and Cambridge, UK, 7 August 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June 2026. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “During the second quarter of FY2026, we continued to make steady progress across the business, building on the momentum achieved in the first quarter. Revenues from PIVLAZ® and QUVIVIQ® in Japan continued to increase steadily. For vamorolone, our treatment for Duchenne Muscular Dystrophy, we obtained key regulatory designations in South Korea that support faster patient access. As we work towards submitting a Marketing Authorization Application in South Korea during 2026, we will continue to work closely with the regulatory authorities...